22.25  -0.74 (-3.22%)		12-15 15:59
Open: 23.44 High: 24.48 Volume: 47,843		Pre. Close: 22.99 Low: 21.5 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	36.58	1-year :	43.68
Resists	First :	31.32	Second :	37.4
Pivot price	25.92
Supports	First :	21.5	Second :	17.88
MAs	MA(5) :	23.9	MA(20) :	26.92
	MA(100) :	27.72	MA(250) :	0
MACD	MACD :	-2.1	Signal :	-1.7
%K %D	K(14,3) :	16.2	D(3) :	24.1
RSI	RSI(14): 31.7
52-week	High :	54.29	Low :	7.19

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PTHS ] has closed below the lower bollinger band by 1.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	24.64 - 24.88	24.88 - 25.02
Low:	21.05 - 21.33	21.33 - 21.49
Close:	21.92 - 22.39	22.39 - 22.67

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Thu, 04 Dec 2025
Pelthos Therapeutics (PTHS) signs PBM deal, opening ZELSUVMI access to 20M lives - Stock Titan

Tue, 02 Dec 2025
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - Sahm

Mon, 01 Dec 2025
Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely - Seeking Alpha

Tue, 25 Nov 2025
Roth Capital Initiates Coverage of Pelthos Therapeutics (PTHS) with Buy Recommendation - Nasdaq

Fri, 14 Nov 2025
Oppenheimer raises Pelthos Therapeutics stock price target on strong drug launch - Investing.com

Thu, 13 Nov 2025
Pelthos Therapeutics Inc. SEC 10-Q Report - TradingView — Track All Markets

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.